United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone
United Therapeutics shares rose 1.4% to $576.30 Tuesday after reporting Phase 3 trial data showing Tyvaso improved lung function and reduced risk of worsening in idiopathic pulmonary fibrosis. The company plans to file for FDA approval by summer’s end. Revenue fell 2% last quarter to $781.5 million, with Tyvaso sales slipping. Liquidia’s rival drug Yutrepia posted $130 million in Q1 sales after last year’s FDA nod.